The document provides an overview of the EVICEL fibrin sealant product, including its performance and market share growth. It discusses EVICEL's new general hemostasis indication, which expands its promotional opportunities in plastic surgery procedures. Guidelines for sales representatives to follow regarding on-label and off-label promotion are also presented.